GI Tract
  • Can Altering the Intestinal Microbiome Reduce Wheat Sensitivity?

Can Altering the Intestinal Microbiome Reduce Wheat Sensitivity?

Amylase trypsin inhibitors (ATIs), which are enzymes in wheat, promote intestinal dysfunction and exacerbate inflammation in response to gluten, researchers show in study of mice published in the June issue of Gastroenterology. Strategies to alter the intestinal microbiome, such as administration of bacteria with ATI-degrading capacity, might be effective for

Read more
  • A Case of Spirochetosis That Resembles IBD

A Case of Spirochetosis That Resembles IBD

Researchers describe a patient with intestinal spirochetosis—a rare intestinal infection caused by Brachyspira aalborgi or Brachyspira pilosicoli that can involve the colon or terminal ileum and mimic inflammatory bowel diseases—in the May issue of Clinical Gastroenterology and Hepatology. Manasi Agrawal et al report the case of a 45-year-old man with HIV infection and an undetectable viral

Read more
  • Can a Food-based Diet Replace Exclusive Enteral Nutrition for Patients With Crohn’s Disease?

Can a Food-based Diet Replace Exclusive Enteral Nutrition for Patients With Crohn’s Disease?

An individualized, food-based diet with similar composition of nutrients to exclusive enteral nutrition (EEN), causes similar changes in the microbiomes of patients with Crohn’s disease (CD), reduces gut inflammation, and is preferred by patients, researchers report in the April issue of Gastroenterology. Non-medical treatments are needed for patients with CD. Diet

Read more
  • Can Surveillance be Extended or Eliminated for Some Patients With Barrett’s Esophagus?

Can Surveillance be Extended or Eliminated for Some Patients With Barrett’s Esophagus?

Two articles in the April issue of Clinical Gastroenterology and Hepatology show that surveillance intervals might be lengthened or even discontinued for subgroups of patients with Barrett’s esophagus. Stable non-dysplastic Barrett’s esophagus (NDBE) has a low risk of progression to high-grade dysplaisa (HGD) or esophageal adenocarcinoma (EAC), Yonne Peters et al

Read more
  • IBD Research Highlights from 2019 ECCO Congress

IBD Research Highlights from 2019 ECCO Congress

A variety of exciting findings from inflammatory bowel disease (IBD) research were presented at the Congress of the European Crohn’s and Colitis Organisation (ECCO), held in Copenhagen, March 7–9. Shixian Hu (Universitair Medisch Centrum Groningen, The Netherlands) reported on associations between genetic factors and the microbiome in patients with IBD.

Read more
  • REVIEW: Combining CRISPR-Cas9 and Organoid Technologies to Study Gastrointestinal Diseases

REVIEW: Combining CRISPR-Cas9 and Organoid Technologies to Study Gastrointestinal Diseases

CRISPR-Cas9 technology can be used to engineer organoids for studies of gastrointestinal development and disease pathogenesis. In the February issue of Gastroenterology, Masayuki Fujii et al review derivation of organoids from human gastrointestinal tissues and how CRISPR-Cas9 has advanced studies of the digestive system. CRISPR-Cas9 genome editing technology allows researchers to

Read more
  • REVIEW: Balancing Benefit vs Risk of Immunosuppressive Therapy for IBD

REVIEW: Balancing Benefit vs Risk of Immunosuppressive Therapy for IBD

Inflammatory bowel diseases (IBD) and their treatments, particularly immunosuppressive drugs, increase risk of infections and cancers. However, by promoting mucosal healing, these agents reduce risks of infections related to intestinal lesions, malnutrition, intravenous devices, and IBD surgeries and reduce risk of cancers associated with chronic mucosal inflammation. Laurent Beaugerie and Julien Kirchgesner

Read more
  • Can an Antibody Against IL13 Be Used to Treat Eosinophilic Esophagitis?

Can an Antibody Against IL13 Be Used to Treat Eosinophilic Esophagitis?

A monoclonal antibody against IL13 reduced histologic and endoscopic features of eosinophilic esophagitis (EoE) in a placebo-controlled phase 2 trial, researchers report in the February issue of Gastroenterology. The antibody, called RPC4046, was well tolerated. EoE is a chronic, immune-mediated disease of the esophagus characterized by eosinophil-mediated mucosal inflammation and

Read more
  • Combined Genetic and Clinical Data Do Not Improve Determination of Risk for Esophageal Adenocarcinoma

Combined Genetic and Clinical Data Do Not Improve Determination of Risk for Esophageal Adenocarcinoma

Addition of genetic information to clinical factors does not increase identification of individuals at risk for esophageal adenocarcinoma, researchers report in the January 2019 issue of Gastroenterology. New screening and risk evaluation methods are needed to improve early detection of esophageal adenocarcinoma, because most patients receive a diagnosis at a late

Read more
  • Simple Process for Generating Unlimited Intestinal Stem Cells From Endoscopic Biopsies

Simple Process for Generating Unlimited Intestinal Stem Cells From Endoscopic Biopsies

An efficient method for cloning gastrointestinal stem cells from biopsies collected during endoscopy is reported in the January isssue of Gastroenterology. A system is needed to isolate, clone, and examine the mucosal stem cells away from confounding effects of immune, stromal, and microbe cells. Markers of stem cells such as

Read more